First Patient Treated in Gene-Therapy Trial to Rejuvenate Cells for Glaucoma
The first person has been enrolled in a gene-therapy trial using 'partial reprogramming' to rejuvenate aged cells in the optic nerve as a potential treatment for glaucoma. The approach involves activating three genes to enable old cells to behave as young cells again. This represents a significant milestone in testing whether cellular rejuvenation can treat age-related blindness.
Researchers have treated the first patient in a highly anticipated gene-therapy trial that aims to reverse cellular aging through a novel technique called 'partial reprogramming.' The trial will assess the safety of activating three specific genes to rejuvenate cells in the optic nerve, with the goal of treating a form of glaucoma—an eye disease that can lead to blindness. This approach represents a new frontier in regenerative medicine, moving beyond traditional treatments to address the underlying cellular aging that contributes to age-related diseases. The trial will provide critical data on whether this method can safely and effectively restore function to aged tissues. Success could open pathways for treating other age-related conditions beyond glaucoma.
Limitations & open questions
The specific identity of the research institution or company leading the trial, the trial's size and duration, and the patient's baseline glaucoma severity are not provided. Additionally, the mechanism by which partial reprogramming avoids the risks associated with full cellular reprogramming (such as tumor formation) is not explained.
What different sources said
- Nature NewsCenter
Daily briefing: Trial to ‘de-age’ cells treats first person
Related
Profilin-1 Deficiency Activates Immune Response Against Breast Cancer in Preclinical Study
Researchers found that removing the Profilin-1 protein from breast cancer cells triggers DNA damage and activates an immune pathway called STING, which recruits cancer-fighting T cells and causes tumor regression in mice. The study used CRISPR gene-editing technology to deplete Profilin-1 and observed that the resulting genomic instability paradoxically strengthens anti-tumor immunity. The findings suggest targeting Profilin-1 could be a new strategy to enhance immunotherapy effectiveness in breast cancer.
Computational Study Explores How Magnetic Fields May Affect Tomato Plant Ion Channels
Researchers used molecular dynamics simulations to investigate how static magnetic fields affect the CNGC6 ion channel in tomato plants, finding that magnetic fields may alter the channel's structure in specific ways. The study was motivated by observations that magnetic treatment of tomato seeds appears to speed germination and improve plant development, though the underlying cellular mechanisms remain unclear. The findings provide a computational foundation for future experimental work, though the authors emphasize this is a preliminary exploratory study requiring validation.
New Algorithm Simplifies Evolutionary Network Reconstruction for Hybridized Species
Researchers developed NetCS, a fast algorithm for reconstructing evolutionary networks in hybridized species that avoids expensive computational bottlenecks. The method works well when given accurate intermediate data but reveals that the real challenge in network inference lies in an earlier reconstruction step. This finding could enable phylogenetic analyses of larger datasets while identifying where future improvements are needed.